GlassScriptPhysician profile
Gregory J Katz
NPI 1184674178
$14,659.70
in general payments reported to CMS, 2019-2025
60 companies · $1,945 in 2025
The $1,945 reported for 2025 was more than what 93% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,112 · 2020: $2,134 · 2021: $2,249 · 2022: $2,224 · 2023: $2,107 · 2024: $1,888 · 2025: $1,945.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,941.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,941.01 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $1,578.39 | 2019-2025 | Airsupra, Farxiga, Breztri |
| Lilly USA, LLC | $1,526.27 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $1,386.99 | 2019-2025 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,188.40 | 2019-2025 | Jardiance, Ofev, Spiriva Respimat |
| Amgen INC. | $915.63 | 2019-2025 | Repatha, Evenity, Otezla |
| Pfizer INC. | $906.15 | 2019-2025 | |
| Novo Nordisk INC | $827.02 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Novartis Pharmaceuticals Corporation | $797.31 | 2019-2025 | |
| Merck Sharp & Dohme LLC | $587.27 | 2019-2025 | Verquvo, Belsomra, Capvaxive |
| Janssen Pharmaceuticals, INC | $579.47 | 2019-2024 | Xarelto |
| Astellas Pharma US INC | $250.43 | 2019-2023 | Veozah, Myrbetriq |
| Allergan, INC. | $242.20 | 2019-2020 | |
| Exact Sciences Corporation | $234.68 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Azurity Pharmaceuticals, INC. | $218.63 | 2023-2024 | Horizant, Horizant |
| Glaxosmithkline, LLC. | $217.16 | 2019-2025 | Shingrix, Arexvy |
Show all 60 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gregory Katz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.